Emmaus Life Sciences (EMMA) reports director Ian Zwicker to step down

Rhea-AI Filing Summary

Emmaus Life Sciences, Inc. reported a board change, disclosing that director Ian Zwicker resigned from the company’s board of directors on December 15, 2025, with the resignation to take effect on December 31, 2025. The filing does not describe any related financial effects or changes to the company’s operations, focusing solely on this governance update. Emmaus remains a Delaware corporation headquartered in Torrance, California, and the report was signed by Chairman and Chief Executive Officer Willis Lee.

false 0000822370 0000822370 2025-12-15 2025-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2025

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35527		87-0419387
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

Resignation of Director

On December 15, 2025, Ian Zwicker resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”), effective December 31, 2025.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the inline XBRL Document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 19, 2025	EMMAUS LIFE SCIENCES, INC.
	By:	/s/ WILLIS LEE
	Name:	Willis Lee
	Title:	Chairman and Chief Executive Officer

2

FAQ

What board change did Emmaus Life Sciences (EMMA) report in this 8-K?

Emmaus Life Sciences reported that Ian Zwicker resigned as a director of the company. The resignation was submitted on December 15, 2025 and is effective December 31, 2025.

When is Ian Zwicker’s resignation from Emmaus Life Sciences (EMMA) effective?

Ian Zwicker’s resignation as a director of Emmaus Life Sciences is effective on December 31, 2025, as disclosed in the report.

Does this Emmaus Life Sciences (EMMA) filing disclose any financial results or earnings data?

No financial results, earnings data, or major transactions are discussed. The filing is limited to the resignation of a director and related disclosure items.

Who signed the Emmaus Life Sciences (EMMA) 8-K reporting the director’s resignation?

The report was signed on behalf of Emmaus Life Sciences, Inc. by Willis Lee, who is identified as Chairman and Chief Executive Officer.

What SEC item does Emmaus Life Sciences (EMMA) use to report the director resignation?

The board change is reported under Item 5.02, which covers the departure of directors or certain officers and related arrangements.

Are there any exhibits attached to this Emmaus Life Sciences (EMMA) 8-K?

Yes. The filing lists Exhibit 104, described as the Cover Page Interactive Data File embedded within the inline XBRL document.